Hubert Chen

Hubert C.
Chen formerly worked at Amgen, Inc., as Associate Director-Medical Sciences from 2004 to 2006, Amylin Pharmaceuticals, Inc., as Senior Director-Clinical Research, Rein Therapeutics, Inc., as Vice President-Clinical Development from 2013 to 2014, The University of California, San Francisco, as Assistant Clinical Professor from 2002 to 2012, The J.
David Gladstone Institutes, as Staff Research Investigator, Regulus Therapeutics, Inc., as Vice President-Translational Medicine from 2009 to 2012, Pelican, Inc., as Chief Medical & Scientific Officer from 2014 to 2018, Metacrine, Inc., as Chief Medical Officer from 2018 to 2021, and Forte Biosciences, Inc., as President & Chief Scientific Officer from 2022 to 2024.
Dr. Chen received his doctorate degree in 1995 from The Trustees of Columbia University in The City of New York and undergraduate degree in 1991 from Stanford University.